Blaine A Pfeifer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6863763/publications.pdf

Version: 2024-02-01

99 papers	4,831 citations	159585 30 h-index	98798 67 g-index
100 all docs	100 docs citations	100 times ranked	5754 citing authors

#	Article	IF	Citations
1	Consolidated plasmid Design for Stabilized Heterologous Production of the complex natural product Siderophore Yersiniabactin. Biotechnology Progress, 2021, 37, e3103.	2.6	3
2	Antibacterial p-Terphenyl with a Rare 2,2â€²-Bithiazole Substructure and Related Compounds Isolated from the Marine-Derived Actinomycete Nocardiopsis sp. HDN154086. Journal of Natural Products, 2021, 84, 1226-1231.	3.0	10
3	Complex natural product production methods and options. Synthetic and Systems Biotechnology, 2021, 6, 1-11.	3.7	10
4	Intranasal Vaccine Delivery Technology for Respiratory Tract Disease Application with a Special Emphasis on Pneumococcal Disease. Vaccines, 2021, 9, 589.	4.4	6
5	Siderophore natural products as pharmaceutical agents. Current Opinion in Biotechnology, 2021, 69, 242-251.	6.6	23
6	An efficient marker recycling system for sequential gene deletion in a deep sea-derived fungus Acremonium sp. HDN16-126. Synthetic and Systems Biotechnology, 2021, 6, 127-133.	3.7	4
7	Salicylate Glucoside as a Nontoxic Plant Protectant Alternative to Salicylic Acid. ACS Agricultural Science and Technology, 2021, 1, 515-521.	2.3	1
8	Vaccine Delivery and Immune Response Basics. Methods in Molecular Biology, 2021, 2183, 1-8.	0.9	11
9	Liposomal Dual Delivery of Both Polysaccharide and Protein Antigens. Methods in Molecular Biology, 2021, 2183, 477-487.	0.9	4
10	A Hybrid Biologicalâ€“Biomaterial Vector for Antigen Delivery. Methods in Molecular Biology, 2021, 2183, 461-475.	0.9	1
11	Liposomal Encapsulation of Polysaccharides (LEPS) as an Effective Vaccine Strategy to Protect Aged Hosts Against S. pneumoniae Infection. Frontiers in Aging, 2021, 2, .	2.6	6
12	Heterologous Biosynthesis of Type II Polyketide Products Using E. coli. ACS Chemical Biology, 2020, 15, 1177-1183.	3.4	31
13	Grafting Activated Graphene Oxide Nanosheets onto Ultrafiltration Membranes Using Polydopamine to Enhance Antifouling Properties. ACS Applied Materials & Interfaces, 2020, 12, 48179-48187.	8.0	24
14	Heterologous biosynthesis as a platform for producing new generation natural products. Current Opinion in Biotechnology, 2020, 66, 123-130.	6.6	19
15	Extended Polysaccharide Analysis within the Liposomal Encapsulation of Polysaccharides System. Materials, 2020, 13, 3320.	2.9	2
16	Monacyclines Gâ€“K and ent-Gephyromycin A, Angucycline Derivatives from the Marine-Derived Streptomyces sp. HDN15129. Journal of Natural Products, 2020, 83, 2749-2755.	3.0	18
17	Flux Balance Analysis for Media Optimization and Genetic Targets to Improve Heterologous Siderophore Production. IScience, 2020, 23, 101016.	4.1	11
18	PEGylated Amine-Functionalized Poly(Îµ-caprolactone) for the Delivery of Plasmid DNA. Materials, 2020, 13, 898.	2.9	8

#	Article	IF	Citations
19	Engineering Escherichia coli for Bacterial Natural Product Production. , 2020, , 136-148.		0
20	Design Variation of a Dual-Antigen Liposomal Vaccine Carrier System. Materials, 2019, 12, 2809.	2.9	3
21	Antigen delivery format variation and formulation stability through use of a hybrid vector. Vaccine: X, 2019, 1, 100012.	2.1	2
22	Loading and releasing ciprofloxacin in photoactivatable liposomes. Biochemical Engineering Journal, 2019, 141, 43-48.	3.6	17
23	A Transition to Targeted or â€˜Smartâ€™ Vaccines: How Understanding Commensal Colonization Can Lead to Selective Vaccination. Pharmaceutical Medicine, 2018, 32, 95-102.	1.9	0
24	Continuous removal of copper, magnesium, and nickel from industrial wastewater utilizing the natural product yersiniabactin immobilized within a packed-bed column. Chemical Engineering Journal, 2018, 343, 173-179.	12.7	23
25	Reconstitution of Kinamycin Biosynthesis within the Heterologous Host Streptomyces albus J1074. Journal of Natural Products, 2018, 81, 72-77.	3.0	35
26	Heterologous erythromycin production across strain and plasmid construction. Biotechnology Progress, 2018, 34, 271-276.	2.6	26
27	Engineering Heterologous Production of Salicylate Glucoside and Glycosylated Variants. Frontiers in Microbiology, 2018, 9, 2241.	3.5	7
28	Engineering a Next-Generation Glycoconjugate-LikeStreptococcus pneumoniaeVaccine. ACS Infectious Diseases, 2018, 4, 1553-1563.	3.8	18
29	Phenotypic Variation during Biofilm Formation: Implications for Anti-Biofilm Therapeutic Design. Materials, 2018, 11, 1086.	2.9	49
30	Constraintâ€based metabolic targets for the improved production of heterologous compounds across molecular classification. AICHE Journal, 2018, 64, 4208-4217.	3.6	1
31	Broadened glycosylation patterning of heterologously produced erythromycin. Biotechnology and Bioengineering, 2018, 115, 2771-2777.	3.3	8
32	Bimodal Targeting Using Sulfonated, Mannosylated <scp>PEI</scp> for Combined Gene Delivery and Photodynamic Therapy. Photochemistry and Photobiology, 2017, 93, 600-608.	2.5	7
33	Comprehensive vaccine design for commensal disease progression. Science Advances, 2017, 3, e1701797.	10.3	28
34	Yersiniabactin metal binding characterization and removal of nickel from industrial wastewater. Biotechnology Progress, 2017, 33, 1548-1554.	2.6	10
35	Increased production of yersiniabactin and an anthranilate analog through media optimization. Biotechnology Progress, 2017, 33, 1193-1200.	2.6	6
36	Pressing diseases that represent promising targets for gene therapy. Discovery Medicine, 2017, 24, 313-322.	0.5	4

#	Article	IF	Citations
37	Editorial overview: Pharmaceutical biotechnology: New approaches for dynamic disease targets. Current Opinion in Biotechnology, 2016, 42, vi-vii.	6.6	0
38	Recent progress in therapeutic natural product biosynthesis using Escherichia coli. Current Opinion in Biotechnology, 2016, 42, 7-12.	6.6	23
39	A copper removal process for water based upon biosynthesis of yersiniabactin, a metal-binding natural product. Chemical Engineering Journal, 2016, 306, 772-776.	12.7	11
40	Improved heterologous production of the nonribosomal peptideâ€polyketide siderophore yersiniabactin through metabolic engineering and induction optimization. Biotechnology Progress, 2016, 32, 1412-1417.	2.6	17
41	E. coli metabolic engineering for gram scale production of a plant-based anti-inflammatory agent. Metabolic Engineering, 2016, 38, 382-388.	7.0	34
42	Mass spectrometry-based metabolomics of value-added biochemicals from Ettlia oleoabundans. Algal Research, 2016, 19, 146-154.	4.6	9
43	In situ pneumococcal vaccine production and delivery through a hybrid biological-biomaterial vector. Science Advances, 2016, 2, e1600264.	10.3	18
44	Molecular variation of the nonribosomal peptideâ€polyketide siderophore yersiniabactin through biosynthetic and metabolic engineering. Biotechnology and Bioengineering, 2016, 113, 1067-1074.	3.3	8
45	Directed vaccination against pneumococcal disease. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 6898-6903.	7.1	39
46	The Continuing Development of E. coli as a Heterologous Host for Complex Natural Product Biosynthesis. Methods in Molecular Biology, 2016, 1401, 121-134.	0.9	13
47	Enhancing vaccine effectiveness with delivery technology. Current Opinion in Biotechnology, 2016, 42, 24-29.	6.6	8
48	Overcoming Gene-Delivery Hurdles: Physiological Considerations for Nonviral Vectors. Trends in Biotechnology, 2016, 34, 91-105.	9.3	132
49	Production of the polyketide 6-deoxyerythronolide B in the heterologous host Bacillus subtilis. Applied Microbiology and Biotechnology, 2016, 100, 1209-1220.	3.6	27
50	Tailoring pathway modularity in the biosynthesis of erythromycin analogs heterologously engineered in E. coli. Science Advances, 2015, 1, e1500077.	10.3	32
51	PEGylated Cationic Polylactides for Hybrid Biosynthetic Gene Delivery. Molecular Pharmaceutics, 2015, 12, 846-856.	4.6	27
52	Total Biosynthesis and Diverse Applications of the Nonribosomal Peptide-Polyketide Siderophore Yersiniabactin. Applied and Environmental Microbiology, 2015, 81, 5290-5298.	3.1	28
53	Influence of molecular weight upon mannosylated bio-synthetic hybrids for targeted antigen presenting cell gene delivery. Biomaterials, 2015, 58, 103-111.	11.4	11
54	Improved Escherichia coli Bactofection and Cytotoxicity by Heterologous Expression of Bacteriophage Î¦X174 Lysis Gene E. Molecular Pharmaceutics, 2015, 12, 1691-1700.	4.6	10

#	Article	IF	Citations
55	Structureâ€“Function Assessment of Mannosylated Poly(Î²-amino esters) upon Targeted Antigen Presenting Cell Gene Delivery. Biomacromolecules, 2015, 16, 1534-1541.	5.4	24
56	Mannosylated poly(beta-amino esters) for targeted antigen presenting cell immune modulation. Biomaterials, 2015, 37, 333-344.	11.4	43
57	Contemporary approaches for nonviral gene therapy. Discovery Medicine, 2015, 19, 447-54.	0.5	11
58	Hybrid biosynthetic gene therapy vector development and dual engineering capacity. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 12360-12365.	7.1	25
59	Heterologous production of plant-derived isoprenoid products in microbes and the application of metabolic engineering and synthetic biology. Current Opinion in Plant Biology, 2014, 19, 8-13.	7.1	38
60	Porphyrinâ€“phospholipid liposomes permeabilized by near-infrared light. Nature Communications, 2014, 5, 3546.	12.8	282
61	Deoxysugar pathway interchange for erythromycin analogues heterologously produced through Escherichia coli. Metabolic Engineering, 2013, 20, 92-100.	7.0	21
62	Overcoming Nonviral Gene Delivery Barriers: Perspective and Future. Molecular Pharmaceutics, 2013, 10, 4082-4098.	4.6	327
63	Poly(ethylene glycol)-block-cationic polylactide nanocomplexes ofÂdiffering charge density for gene delivery. Biomaterials, 2013, 34, 9688-9699.	11.4	69
64	Synthesis of Cationic Polylactides with Tunable Charge Densities as Nanocarriers for Effective Gene Delivery. Molecular Pharmaceutics, 2013, 10, 1138-1145.	4.6	56
65	Improved heterologous erythromycin A production through expression plasmid reâ€design. Biotechnology Progress, 2013, 29, 862-869.	2.6	20
66	Metabolic and pathway engineering to influence native and altered erythromycin production through E. coli. Metabolic Engineering, 2013, 19, 42-49.	7.0	29
67	Engineering E. coli for triglyceride accumulation through native and heterologous metabolic reactions. Applied Microbiology and Biotechnology, 2013, 97, 2753-2759.	3.6	17
68	Polymyxin B Treatment Improves Bactofection Efficacy and Reduces Cytotoxicity. Molecular Pharmaceutics, 2013, 10, 4301-4308.	4.6	11
69	Toward Biosynthetic Design and Implementation of Escherichia coli-Derived Paclitaxel and Other Heterologous Polyisoprene Compounds. Applied and Environmental Microbiology, 2012, 78, 2497-2504.	3.1	30
70	Downstream reactions and engineering in the microbially reconstituted pathway for Taxol. Applied Microbiology and Biotechnology, 2012, 94, 841-849.	3.6	44
71	Improved E. coli erythromycin a production through the application of metabolic and bioprocess engineering. Biotechnology Progress, 2012, 28, 292-296.	2.6	20
72	Analysis of heterologous taxadiene production in K- and B-derived Escherichia coli. Applied Microbiology and Biotechnology, 2012, 93, 1651-1661.	3.6	56

#	Article	IF	Citations
73	Computational identification of gene over-expression targets for metabolic engineering of taxadiene production. Applied Microbiology and Biotechnology, 2012, 93, 2063-2073.	3.6	56
74	Methods and options for the heterologous production of complex natural products. Natural Product Reports, 2011, 28, 125-151.	10.3	138
75	Simultaneous production and partitioning of heterologous polyketide and isoprenoid natural products in an Escherichia coli two-phase bioprocess. Journal of Industrial Microbiology and Biotechnology, 2011, 38, 1809-1820.	3.0	13
76	Multiâ€factorial engineering of heterologous polyketide production in Escherichia coli reveals complex pathway interactions. Biotechnology and Bioengineering, 2011, 108, 1360-1371.	3.3	26
77	Investigating the role of native propionylâ€CoA and methylmalonylâ€CoA metabolism on heterologous polyketide production in Escherichia coli. Biotechnology and Bioengineering, 2010, 105, 567-573.	3.3	56
78	Computational analysis of phenotypic space in heterologous polyketide biosynthesisâ€"Applications to Escherichia coli, Bacillus subtilis, and Saccharomyces cerevisiae. Journal of Theoretical Biology, 2010, 262, 197-207.	1.7	16
79	Metabolic flux analysis and pharmaceutical production. Metabolic Engineering, 2010, 12, 81-95.	7.0	101
80	Complete Biosynthesis of Erythromycin A and Designed Analogs Using E. coli as a Heterologous Host. Chemistry and Biology, 2010, 17, 1232-1240.	6.0	123
81	Isoprenoid Pathway Optimization for Taxol Precursor Overproduction in Escherichia coli. Science, 2010, 330, 70-74.	12.6	1,426
82	Dihydrochalcomycin Production and Glycosyltransferase from Streptomyces SP. KCTC 0041BP. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2010, 20, 171-5.	0.7	0
83	Efficient experimental design and microâ€scale medium enhancement of 6â€deoxyerythronolide B production through Escherichia coli. Biotechnology Progress, 2009, 25, 1364-1371.	2.6	12
84	A Comparison Between Polymeric Microsphere and Bacterial Vectors for Macrophage P388D1 Gene Delivery. Pharmaceutical Research, 2008, 25, 1202-1208.	3.5	18
85	Polyketide analysis using mass spectrometry, evaporative light scattering, and charged aerosol detector systems. Analytical and Bioanalytical Chemistry, 2008, 390, 1189-1193.	3.7	23
86	A high-throughput comparison of recombinant gene expression parameters for E. coli-mediated gene transfer to P388D1 macrophage cells. Journal of Biotechnology, 2008, 137, 59-64.	3.8	11
87	6-Deoxyerythronolide B production through chromosomal localization of the deoxyerythronolide B synthase genes in E. coli. Metabolic Engineering, 2008, 10, 33-38.	7.0	34
88	Bacterial Hosts for Natural Product Production. Molecular Pharmaceutics, 2008, 5, 212-225.	4.6	85
89	Natural Products and Production Systems: Opening Comments. Molecular Pharmaceutics, 2008, 5, 165-166.	4.6	2
90	Engineering Bacterial Vectors for Delivery of Genes and Proteins to Antigen-Presenting Cells. Molecular Pharmaceutics, 2007, 4, 4-17.	4.6	13

#	Article	IF	Citations
91	Improving heterologous polyketide production in Escherichia coli by overexpression of an S-adenosylmethionine synthetase gene. Applied Microbiology and Biotechnology, 2007, 77, 367-373.	3.6	34
92	Poly(ester-anhydride):poly(Î²-amino ester) micro- and nanospheres: DNA encapsulation and cellular transfection. International Journal of Pharmaceutics, 2005, 304, 210-219.	5.2	36
93	Formulation and surface modification of poly(ester-anhydride) micro- and nanospheres. Biomaterials, 2005, 26, 117-124.	11.4	63
94	Precursor-Directed polyketide biosynthesis in Escherichia coli. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 3701-3704.	2.2	25
95	Biosynthesis of Yersiniabactin, a Complex Polyketide-Nonribosomal Peptide, Using Escherichia coli as a Heterologous Host. Applied and Environmental Microbiology, 2003, 69, 6698-6702.	3.1	111
96	A specific role of the Saccharopolyspora erythraea thioesterase II gene in the function of modular polyketide synthases. Microbiology (United Kingdom), 2003, 149, 2213-2225.	1.8	42
97	Process and Metabolic Strategies for Improved Production of Escherichia coli -Derived 6-Deoxyerythronolide B. Applied and Environmental Microbiology, 2002, 68, 3287-3292.	3.1	87
98	Enhancing the Atom Economy of Polyketide Biosynthetic Processes through Metabolic Engineering. Biotechnology Progress, 2001, 17, 612-617.	2.6	48
99	Biosynthesis of Polyketides in Heterologous Hosts. Microbiology and Molecular Biology Reviews, 2001, 65, 106-118.	6.6	225